Background: Serum electrolytes, Creatinine, and thyroid profile play an important role in 131I treated patients of thyroid disorders.
Objectives: To determine the effect of radioactive iodine (131I) on renal parameters, serum electrolytes and the correlation among TFT’S, creatinine, and chloride levels before and after I131 treatment in thyroid disorders.
Methods: The study was performed on 55 patients of thyrotoxicosis with age ranging from 16-65 years (mean age= 41±14years and BMI=24.8±4.46). The significance of the differences between the results of 1st, 2nd, and 3rd-time serum analysis was assessed by paired Student's t-test. Association between parameters was assessed by Spearman correlation analysis.
Results: 40 patients were taking Carbimazole, and 15 were directly recommended for I131 therapy. Strongly significant variations were observed for TFT’S (T3=0.012, T4 =0.017, and TSH=0. 001) during the follow-up treatment. Before taking I131 (Serum analyzed at 1st time), there observed negative correlation of T3(r=-.46, p=0. 002) and TSH (r=-0.31, p=0.02) with creatinine, and positive correlation of TSH(r=0.29,p=0.02) with chloride. BMI was negatively correlated with potassium(r=-0.30, p=0.02). At the 2nd time (after stopping the Carbimazole), no correlation results were observed. Two months after oral administration of 131I, creatinine, and chloride level was significantly increased (p=0.000), (P=0. 03) respectively, but had no correlation with TFT’S.
Conclusion: Our findings suggest that patients with goiter (diffused or toxic) have association of TFT’S and BMI with serum electrolytes and creatinine, 131I therapy is also associated with the increase in creatinine and chloride levels of patients leading to kidney problems.
Keywords: Goiter, carbimazol, creatinine, thyroid function tests, chloride, thyrotoxicosis, 131I.
[http://dx.doi.org/10.1210/jc.2003-031832] [PMID: 15240580]
[http://dx.doi.org/10.1007/s00405-011-1502-5] [PMID: 21298390]
[http://dx.doi.org/10.1146/annurev.nu.10.070190.000321] [PMID: 1696490]
[http://dx.doi.org/10.1089/thy.2010.0417] [PMID: 21510801]
[http://dx.doi.org/10.1007/s00268-002-6824-4] [PMID: 12658498]
[http://dx.doi.org/10.1530/acta.0.1120494] [PMID: 3529785]
[http://dx.doi.org/10.1001/archinte.159.1.79] [PMID: 9892334]
[http://dx.doi.org/10.1089/thy.2013.0110] [PMID: 24093878]
[http://dx.doi.org/10.4414/smw.2012.13669] [PMID: 22987514]
[http://dx.doi.org/10.1111/j.1445-2197.2007.04286.x] [PMID: 17931253]
(b)Martino, E.; Bartalena, L.; Bogazzi, F.; Braverman, L.E. The effects of amiodarone on the thyroid.. Endocr. Rev, 2001, 22(2), 240-254.
[http://dx.doi.org/10.1034/j.1600-0773.2003.920107.x] [PMID: 12710596]
[http://dx.doi.org/10.1002/jcla.22188] [PMID: 28220977]
[http://dx.doi.org/10.1016/j.clinbiochem.2011.10.012] [PMID: 22061337]
[http://dx.doi.org/10.1016/S0272-6386(96)90539-9] [PMID: 8659492]